nach oben

Erschienen in:

25.07.2019 | Review

New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism

verfasst von: Stephanie Eid, Kelli M. Sas, Steven F. Abcouwer, Eva L. Feldman, Thomas W. Gardner, Subramaniam Pennathur, Patrice E. Fort

Erschienen in: Diabetologia | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Diabetes adversely affects multiple organs, including the kidney, eye and nerve, leading to diabetic kidney disease, diabetic retinopathy and diabetic neuropathy, respectively. In both type 1 and type 2 diabetes, tissue damage is organ specific and is secondary to a combination of multiple metabolic insults. Hyperglycaemia, dyslipidaemia and hypertension combine with the duration and type of diabetes to define the distinct pathophysiology underlying diabetic kidney disease, diabetic retinopathy and diabetic neuropathy. Only recently have the commonalities and differences in the metabolic basis of these tissue-specific complications, particularly those involving local and systemic lipids, been systematically examined. This review focuses on recent progress made using preclinical models and human-based approaches towards understanding how bioenergetics and metabolomic profiles contribute to diabetic kidney disease, diabetic retinopathy and diabetic neuropathy. This new understanding of the biology of complication-prone tissues highlights the need for organ-specific interventions in the treatment of diabetic complications.

Nur mit Berechtigung zugänglich

International Diabetes Federation (2017) Diabetes facts and figures. Available from https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Accessed 11 July 2019

Imperatore G, Boyle JP, Thompson TJ et al (2012) Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 35(12):2515–2520. https://doi.org/10.2337/dc12-0669 CrossRefPubMedPubMedCentral

Mayer-Davis EJ, Lawrence JM, Dabelea D et al (2017) Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med 376(15):1419–1429. https://doi.org/10.1056/NEJMoa1610187 CrossRefPubMedPubMedCentral

Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93(1):137–188. https://doi.org/10.1152/physrev.00045.2011 CrossRefPubMed

United States Renal Data System (2018) 2018 annual data report. Available from www.usrds.org/adrhighlights.aspx. Accessed 11 July 2019

Persson F, Rossing P (2018) Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl 8(1):2–7. https://doi.org/10.1016/j.kisu.2017.10.003 CrossRef

Choudhury D, Tuncel M, Levi M (2010) Diabetic nephropathy — a multifaceted target of new therapies. Discov Med 10(54):406–415PubMed

Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564. https://doi.org/10.2337/dc11-1909 CrossRefPubMedPubMedCentral

Abcouwer SF, Gardner TW (2014) Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci 1311(1):174–190. https://doi.org/10.1111/nyas.12412 CrossRefPubMedPubMedCentral

10.

Duh EJ, Sun JK, Stitt AW (2017) Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2(14):e93751. https://doi.org/10.1172/jci.insight.93751 CrossRefPubMedCentral

11.

Rubsam A, Parikh S, Fort PE (2018) Role of Inflammation in Diabetic Retinopathy. Int J Mol Sci 19(4):942. https://doi.org/10.3390/ijms19040942 CrossRefPubMedCentral

12.

Callaghan BC, Price RS, Feldman EL (2015) Distal Symmetric Polyneuropathy: A Review. JAMA 314(20):2172–2181. https://doi.org/10.1001/jama.2015.13611 CrossRefPubMedPubMedCentral

13.

Feldman EL, Nave KA, Jensen TS, Bennett DLH (2017) New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 93(6):1296–1313. https://doi.org/10.1016/j.neuron.2017.02.005 CrossRefPubMedPubMedCentral

14.

Dyck PJ, Giannini C (1996) Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 55(12):1181–1193. https://doi.org/10.1097/00005072-199612000-00001 CrossRefPubMed

15.

Shamoon H, Duffy H, Fleischer N et al (1993) The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes-Mellitus. N Engl J Med 329:977–986CrossRef

16.

Callaghan BC, Little AA, Feldman EL, Hughes RA (2012) Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 6:CD007543. https://doi.org/10.1002/14651858.CD007543.pub2 CrossRef

17.

King P, Peacock I, Donnelly R (1999) The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 48:643–648CrossRefPubMedPubMedCentral

18.

Gaede PH, Jepsen PV, Larsen JN, Jensen GV, Parving HH, Pedersen OB (2003) The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes [article in Danish]. Ugeskr Laeger 165(26):2658–2661PubMed

19.

Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139. https://doi.org/10.1056/NEJMoa0808431 CrossRefPubMed

20.

Terry T, Raravikar K, Chokrungvaranon N, Reaven PD (2012) Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep 14(1):79–88. https://doi.org/10.1007/s11886-011-0238-6 CrossRefPubMed

21.

Zoungas S, Arima H, Gerstein HC et al (2017) Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5(6):431–437. https://doi.org/10.1016/S2213-8587(17)30104-3 CrossRefPubMed

22.

Callaghan BC, Xia R, Banerjee M et al (2016) Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status. Diabetes Care 39(5):801–807. https://doi.org/10.2337/dc16-0081 CrossRefPubMedPubMedCentral

23.

Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070. https://doi.org/10.1161/CIRCRESAHA.110.223545 CrossRefPubMedPubMedCentral

24.

Feldman AL, Griffin SJ, Fharm E et al (2017) Screening for type 2 diabetes: do screen-detected cases fare better? Diabetologia 60(11):2200–2209. https://doi.org/10.1007/s00125-017-4402-4 CrossRefPubMedPubMedCentral

25.

Tang WH, Martin KA, Hwa J (2012) Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 3:87CrossRefPubMedPubMedCentral

26.

Sas KM, Kayampilly P, Byun J et al (2016) Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight 1:e86976CrossRefPubMedPubMedCentral

27.

Afshinnia F, Rajendiran TM, Karnovsky A et al (2016) Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep 1(4):256–268. https://doi.org/10.1016/j.ekir.2016.08.007 CrossRefPubMedPubMedCentral

28.

Afshinnia F, Rajendiran TM, Soni T et al (2018) Impaired beta-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. J Am Soc Nephrol 29(1):295–306. https://doi.org/10.1681/ASN.2017030350 CrossRefPubMed

29.

Afshinnia F, Rajendiran TM, Wernisch S et al (2018) Lipidomics and Biomarker Discovery in Kidney Disease. Semin Nephrol 38(2):127–141. https://doi.org/10.1016/j.semnephrol.2018.01.004 CrossRefPubMedPubMedCentral

30.

Sas KM, Lin J, Rajendiran TM et al (2018) Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model. J Lipid Res 59(2):173–183. https://doi.org/10.1194/jlr.M077222 CrossRefPubMed

31.

Sas KM, Nair V, Byun J et al (2015) Targeted Lipidomic and Transcriptomic Analysis Identifies Dysregulated Renal Ceramide Metabolism in a Mouse Model of Diabetic Kidney Disease. J Proteomics Bioinform s14(Suppl 14). https://doi.org/10.4172/jpb.S14-002

32.

Freeman OJ, Unwin RD, Dowsey AW et al (2016) Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental Diabetic Neuropathy. Diabetes 65(1):228–238. https://doi.org/10.2337/db15-0835 CrossRefPubMed

33.

Priyadarsini S, McKay TB, Sarker-Nag A et al (2016) Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. Exp Eye Res 153:90–100. https://doi.org/10.1016/j.exer.2016.10.010 CrossRefPubMedPubMedCentral

34.

Hur J, Sullivan KA, Pande M et al (2011) The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 134(11):3222–3235. https://doi.org/10.1093/brain/awr228 CrossRefPubMedPubMedCentral

35.

Chen SC, Tseng CH (2013) Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud 10(2-3):88–100. https://doi.org/10.1900/RDS.2013.10.88 CrossRefPubMedPubMedCentral

36.

Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4(8):444–452. https://doi.org/10.1038/ncpendmet0894 CrossRefPubMed

37.

Maqbool M, Cooper ME, Jandeleit-Dahm KAM (2018) Cardiovascular Disease and Diabetic Kidney Disease. Semin Nephrol 38(3):217–232. https://doi.org/10.1016/j.semnephrol.2018.02.003 CrossRefPubMed

38.

Davis TM, Ting R, Best JD et al (2011) Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54(2):280–290. https://doi.org/10.1007/s00125-010-1951-1 CrossRefPubMed

39.

Peng H, Luo P, Li Y et al (2013) Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1. PLoS One 8(11):e80009. https://doi.org/10.1371/journal.pone.0080009 CrossRefPubMedPubMedCentral

40.

Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17(7):2006–2016. https://doi.org/10.1681/ASN.2006010012 CrossRefPubMed

41.

Colhoun HM, Betteridge DJ, Durrington PN et al (2009) Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54(5):810–819. https://doi.org/10.1053/j.ajkd.2009.03.022 CrossRefPubMed

42.

Rahman M, Baimbridge C, Davis BR et al (2008) Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 52(3):412–424. https://doi.org/10.1053/j.ajkd.2008.05.027 CrossRefPubMedPubMedCentral

43.

Giunti S, Calkin AC, Forbes JM et al (2010) The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol 299(3):F528–F535. https://doi.org/10.1152/ajprenal.00127.2010 CrossRefPubMed

44.

Chew EY, Klein ML, Ferris FL 3rd et al (1996) Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114(9):1079–1084. https://doi.org/10.1001/archopht.1996.01100140281004 CrossRefPubMed

45.

Klein BE, Myers CE, Howard KP, Klein R (2015) Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. JAMA Ophthalmol 133(5):503–510. https://doi.org/10.1001/jamaophthalmol.2014.5108 CrossRefPubMedPubMedCentral

46.

Romero P, Salvat M, Fernandez J, Baget M, Martinez I (2007) Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients. J Diabetes Complicat 21(2):93–100. https://doi.org/10.1016/j.jdiacomp.2006.04.001 CrossRef

47.

Gupta A, Gupta V, Thapar S, Bhansali A (2004) Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 137(4):675–682. https://doi.org/10.1016/j.ajo.2003.11.017 CrossRefPubMed

48.

Sen K, Misra A, Kumar A, Pandey RM (2002) Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 56(1):1–11. https://doi.org/10.1016/S0168-8227(01)00341-2 CrossRefPubMed

49.

Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696. https://doi.org/10.1016/S0140-6736(04)16895-5 CrossRefPubMed

50.

Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016CrossRef

51.

Kang EY, Chen TH, Garg SJ et al (2019) Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmol 137(4):363–371. https://doi.org/10.1001/jamaophthalmol.2018.6399 CrossRefPubMedPubMedCentral

52.

ACCORD Study Group, ACCORD Eye Study Group (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363(3):233–244. https://doi.org/10.1056/NEJMoa1001288 CrossRef

53.

Keech AC, Mitchell P, Summanen PA et al (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370(9600):1687–1697. https://doi.org/10.1016/S0140-6736(07)61607-9 CrossRefPubMed

54.

Zhou Y, Wang C, Shi K, Yin X (2018) Relationship between dyslipidemia and diabetic retinopathy: a systematic review and meta-analysis. Medicine 97(36):e12283. https://doi.org/10.1097/MD.0000000000012283 CrossRefPubMedPubMedCentral

55.

Liu Q, Zhang X, Cheng R, Ma JX, Yi J, Li J (2019) Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation. Cell Tissue Res 376(2):165–177. https://doi.org/10.1007/s00441-018-2974-z CrossRefPubMed

56.

Pearsall EA, Cheng R, Matsuzaki S et al (2019) Neuroprotective effects of PPARalpha in retinopathy of type 1 diabetes. PLoS One 14(2):e0208399. https://doi.org/10.1371/journal.pone.0208399 CrossRefPubMedPubMedCentral

57.

Wang N, Zou C, Zhao S, Wang Y, Han C, Zheng Z (2018) Fenofibrate Exerts Protective Effects in Diabetic Retinopathy via Inhibition of the ANGPTL3 Pathway. Invest Ophthalmol Vis Sci 59(10):4210–4217. https://doi.org/10.1167/iovs.18-24155 CrossRefPubMed

58.

Liu Q, Zhang F, Zhang X et al (2018) Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. Mol Cell Biochem 445(1-2):105–115. https://doi.org/10.1007/s11010-017-3256-x CrossRefPubMed

59.

Smith AG, Singleton JR (2013) Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complicat 27(5):436–442. https://doi.org/10.1016/j.jdiacomp.2013.04.003 CrossRef

60.

Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL (2009) Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58(7):1634–1640. https://doi.org/10.2337/db08-1771 CrossRefPubMedPubMedCentral

61.

Rajamani K, Colman PG, Li LP et al (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373(9677):1780–1788. https://doi.org/10.1016/S0140-6736(09)60698-X CrossRefPubMedPubMedCentral

62.

Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL (2009) Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 58(10):2376–2385. https://doi.org/10.2337/db09-0047 CrossRefPubMedPubMedCentral

63.

Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U (2014) Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 55(3):561–572. https://doi.org/10.1194/jlr.P040501 CrossRefPubMedPubMedCentral

64.

Rajagopal R, Zhang S, Wei X et al (2018) Retinal de novo lipogenesis coordinates neurotrophic signaling to maintain vision. JCI Insight 3(1):e97076. https://doi.org/10.1172/jci.insight.97076 CrossRefPubMedCentral

65.

McGregor BA, Eid S, Rumora AE et al (2018) Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy. Sci Rep 8(1):17678. https://doi.org/10.1038/s41598-018-36098-5 CrossRefPubMedPubMedCentral

66.

Goldberg IJ (2001) Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 86(3):965–971. https://doi.org/10.1210/jcem.86.3.7304 CrossRefPubMed

67.

Rhee EP, Cheng S, Larson MG et al (2011) Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 121(4):1402–1411. https://doi.org/10.1172/JCI44442 CrossRefPubMedPubMedCentral

68.

Gong Y, Fu Z, Liegl R, Chen J, Hellstrom A, Smith LE (2017) ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases. Am J Clin Nutr 106(1):16–26. https://doi.org/10.3945/ajcn.117.153825 CrossRefPubMedPubMedCentral

69.

Tikhonenko M, Lydic TA, Wang Y et al (2010) Remodeling of retinal Fatty acids in an animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2 and Elovl4. Diabetes 59(1):219–227. https://doi.org/10.2337/db09-0728 CrossRefPubMed

70.

Connor KM, SanGiovanni JP, Lofqvist C et al (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13(7):868–873. https://doi.org/10.1038/nm1591 CrossRefPubMedPubMedCentral

71.

Kady NM, Liu X, Lydic TA et al (2018) ELOVL4-Mediated Production of Very Long-Chain Ceramides Stabilizes Tight Junctions and Prevents Diabetes-Induced Retinal Vascular Permeability. Diabetes 67(4):769–781. https://doi.org/10.2337/db17-1034 CrossRefPubMedPubMedCentral

72.

Callaghan BC, Gao LL, Li YF et al (2018) Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neur 5(4):397–405. https://doi.org/10.1002/acn3.531 CrossRef

73.

Duran AM, Salto LM, Camara J et al (2019) Effects of omega-3 polyunsaturated fatty-acid supplementation on neuropathic pain symptoms and sphingosine levels in Mexican-Americans with type 2 diabetes. Diabetes Metab Syndr Obes 12:109–120. https://doi.org/10.2147/DMSO.S187268 CrossRefPubMedPubMedCentral

74.

Yorek MA (2018) The Potential Role of Fatty Acids in Treating Diabetic Neuropathy. Curr Diab Rep 18(10):86. https://doi.org/10.1007/s11892-018-1046-9 CrossRefPubMedPubMedCentral

75.

Pande M, Hur J, Hong Y et al (2011) Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes 60(7):1981–1989. https://doi.org/10.2337/db10-1541 CrossRefPubMedPubMedCentral

76.

Rumora AE, Lentz SI, Hinder LM et al (2018) Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. FASEB J 32(1):195–207. https://doi.org/10.1096/fj.201700206R CrossRefPubMed

77.

Kwon B, Lee HK, Querfurth HW (2014) Oleate prevents palmitate-induced mitochondrial dysfunction, insulin resistance and inflammatory signaling in neuronal cells. Biochim Biophys Acta 1843(7):1402–1413. https://doi.org/10.1016/j.bbamcr.2014.04.004 CrossRefPubMed

78.

Schooneman MG, Vaz FM, Houten SM, Soeters MR (2013) Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62(1):1–8. https://doi.org/10.2337/db12-0466 CrossRefPubMed

79.

Viader A, Sasaki Y, Kim S et al (2013) Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron 77(5):886–898. https://doi.org/10.1016/j.neuron.2013.01.012 CrossRefPubMedPubMedCentral

80.

Ding L, Cheng R, Hu Y et al (2014) Peroxisome proliferator-activated receptor alpha protects capillary pericytes in the retina. Am J Pathol 184(10):2709–2720. https://doi.org/10.1016/j.ajpath.2014.06.021 CrossRefPubMedPubMedCentral

81.

Guan Y (2004) Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15(11):2801–2815. https://doi.org/10.1097/01.ASN.0000139067.83419.46 CrossRefPubMed

82.

Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G (2005) Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45(3):485–493. https://doi.org/10.1053/j.ajkd.2004.11.004 CrossRefPubMed

83.

Fu D, Yu JY, Wu M et al (2014) Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res 55(5):860–869. https://doi.org/10.1194/jlr.M045401 CrossRefPubMedPubMedCentral

84.

Hinder LM, Figueroa-Romero C, Pacut C et al (2014) Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction. Antioxid Redox Signal 21(4):588–600. https://doi.org/10.1089/ars.2013.5248 CrossRefPubMedPubMedCentral

85.

Kang HM, Ahn SH, Choi P et al (2015) Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21(1):37–46. https://doi.org/10.1038/nm.3762 CrossRefPubMed

86.

Yuan H, Reddy MA, Deshpande S et al (2016) Epigenetic Histone Modifications Involved in Profibrotic Gene Regulation by 12/15-Lipoxygenase and Its Oxidized Lipid Products in Diabetic Nephropathy. Antioxid Redox Signal 24(7):361–375. https://doi.org/10.1089/ars.2015.6372 CrossRefPubMedPubMedCentral

87.

He W, Miao FJ, Lin DC et al (2004) Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429(6988):188–193. https://doi.org/10.1038/nature02488 CrossRefPubMed

88.

You YH, Quach T, Saito R, Pham J, Sharma K (2016) Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease. J Am Soc Nephrol 27(2):466–481. https://doi.org/10.1681/ASN.2015030302 CrossRefPubMed

89.

Joyal JS, Sun Y, Gantner ML et al (2016) Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat Med 22(4):439–445. https://doi.org/10.1038/nm.4059 CrossRefPubMedPubMedCentral

90.

Willems D, Dorchy H, Dufrasne D (1998) Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis 137(Suppl 1):S61–S64. https://doi.org/10.1016/S0021-9150(97)00320-1 CrossRefPubMed

91.

Martensson CU, Doan KN, Becker T (2017) Effects of lipids on mitochondrial functions. Biochim Biophys Acta Mol Cell Biol Lipids 1862(1):102–113. https://doi.org/10.1016/j.bbalip.2016.06.015 CrossRefPubMed

92.

Chicco AJ, Sparagna GC (2007) Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 292(1):C33–C44. https://doi.org/10.1152/ajpcell.00243.2006 CrossRefPubMed

93.

Darshi M, Van Espen B, Sharma K (2016) Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer. Am J Nephrol 44(2):92–103. https://doi.org/10.1159/000447954 CrossRefPubMed

94.

Szeto HH, Liu S, Soong Y et al (2017) Mitochondria Protection after Acute Ischemia Prevents Prolonged Upregulation of IL-1β and IL-18 and Arrests CKD. J Am Soc Nephrol 28(5):1437–1449. https://doi.org/10.1681/ASN.2016070761 CrossRefPubMed

95.

Szeto HH, Liu S, Soong Y et al (2011) Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol 22(6):1041–1052. https://doi.org/10.1681/ASN.2010080808 CrossRefPubMedPubMedCentral

96.

Alam NM, Mills WC, Wong AA, Douglas RM, Szeto HH, Prusky GT (2015) A mitochondrial therapeutic reverses visual decline in mouse models of diabetes. Dis Model Mech 8(7):701–710. https://doi.org/10.1242/dmm.020248 CrossRefPubMedPubMedCentral

97.

Yin X, Manczak M, Reddy PH (2016) Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington’s disease. Hum Mol Genet 25(9):1739–1753. https://doi.org/10.1093/hmg/ddw045 CrossRefPubMedPubMedCentral

98.

Liu JJ, Green P, John Mann J, Rapoport SI, Sublette ME (2015) Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res 1597:220–246. https://doi.org/10.1016/j.brainres.2014.11.059 CrossRefPubMed

99.

Li MY, Wang YY, Cao R et al (2015) Dietary fish oil inhibits mechanical allodynia and thermal hyperalgesia in diabetic rats by blocking nuclear factor-kappaB-mediated inflammatory pathways. J Nutr Biochem 26(11):1147–1155. https://doi.org/10.1016/j.jnutbio.2015.05.005 CrossRefPubMed

100.

Han E, Yun Y, Kim G et al (2016) Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia. PLoS One 11(5):e0154683. https://doi.org/10.1371/journal.pone.0154683 CrossRefPubMedPubMedCentral

101.

Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V (2017) Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. Neurology 88(24):2294–2301. https://doi.org/10.1212/WNL.0000000000004033 CrossRefPubMedPubMedCentral

102.

Sala-Vila A, Diaz-Lopez A, Valls-Pedret C et al (2016) Dietary Marine omega-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial. JAMA Ophthalmol 134(10):1142–1149. https://doi.org/10.1001/jamaophthalmol.2016.2906 CrossRefPubMed

103.

Herman-Edelstein M, Weinstein T, Levi M (2018) Bile acid receptors and the kidney. Curr Opin Nephrol Hypertens 27(1):56–62. https://doi.org/10.1097/MNH.0000000000000374 CrossRefPubMed

104.

Wang XX, Wang D, Luo Y et al (2018) FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol 29(1):118–137. https://doi.org/10.1681/ASN.2017020222 CrossRefPubMed

105.

Hammer SS, Beli E, Kady N et al (2017) The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor. EBioMedicine 22:181–190. https://doi.org/10.1016/j.ebiom.2017.07.008 CrossRefPubMedPubMedCentral

106.

Cermenati G, Abbiati F, Cermenati S et al (2012) Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J Lipid Res 53(2):300–310. https://doi.org/10.1194/jlr.M021188 CrossRefPubMedPubMedCentral

107.

Gavini CK, Bookout AL, Bonomo R, Gautron L, Lee S, Mansuy-Aubert V (2018) Liver X Receptors Protect Dorsal Root Ganglia from Obesity-Induced Endoplasmic Reticulum Stress and Mechanical Allodynia. Cell Rep 25(2):271–277 e274. https://doi.org/10.1016/j.celrep.2018.09.046 CrossRefPubMedPubMedCentral

108.

Dutta T, Chai HS, Ward LE et al (2012) Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes 61(5):1004–1016. https://doi.org/10.2337/db11-0874 CrossRefPubMedPubMedCentral

109.

Fort PE, Losiewicz MK, Reiter CE et al (2011) Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS One 6(10):e26498. https://doi.org/10.1371/journal.pone.0026498 CrossRefPubMedPubMedCentral

110.

Hinder LM, Murdock BJ, Park M et al (2018) Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story. Exp Neurol 305:33–43. https://doi.org/10.1016/j.expneurol.2018.03.011 CrossRefPubMedPubMedCentral

111.

Hinder LM, Park M, Rumora AE et al (2017) Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease. J Cell Mol Med 21(9):2140–2152. https://doi.org/10.1111/jcmm.13136 CrossRefPubMedPubMedCentral

112.

Crosby-Nwaobi R, Chatziralli I, Sergentanis T, Dew T, Forbes A, Sivaprasad S (2015) Cross Talk between Lipid Metabolism and Inflammatory Markers in Patients with Diabetic Retinopathy. J Diabetes Res 2015:191382CrossRefPubMedPubMedCentral

113.

Herder C, Lankisch M, Ziegler D et al (2009) Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 32(4):680–682. https://doi.org/10.2337/dc08-2011 CrossRefPubMedPubMedCentral

114.

Trevisan R, Nosadini R, Fioretto P et al (1987) Metabolic control of kidney hemodynamics in normal and insulin-dependent diabetic subjects. Effects of acetoacetic, lactic, and acetic acids. Diabetes 36(9):1073–1081. https://doi.org/10.2337/diab.36.9.1073 CrossRefPubMed

115.

Gowda K, Zinnanti WJ, LaNoue KF (2011) The influence of diabetes on glutamate metabolism in retinas. J Neurochem 117(2):309–320. https://doi.org/10.1111/j.1471-4159.2011.07206.x CrossRefPubMed

Titel: New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism
verfasst von: Stephanie Eid
Kelli M. Sas
Steven F. Abcouwer
Eva L. Feldman
Thomas W. Gardner
Subramaniam Pennathur
Patrice E. Fort
Publikationsdatum: 25.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 9/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-019-4959-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor

miR-17-92 and miR-106b-25 clusters regulate beta cell mitotic checkpoint and insulin secretion in mice

Oestrogen receptor β mediates the actions of bisphenol-A on ion channel expression in mouse pancreatic beta cells

Biomarker panels associated with progression of renal disease in type 1 diabetes

CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]